Kala Pharmaceuticals Presents Data Demonstrating Topical Delivery to Posterior Segment of the Eye
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to enable effective local treatment of ocular diseases, announced today the presentation of preclinical data which demonstrated that topical delivery of a small molecule receptor tyrosine kinase inhibitor (RTKi) formulated utilizing Kala’s proprietary mucosal-penetrating particle (MPP) technology significantly enhanced drug levels in the retina. Drug levels in the front of the eye were tunable depending on the release rate of MPP used. Kala presented these data at the Controlled-Release Society (CRS) 2013 Annual Meeting, in Honolulu, Hawaii on July 21-24, 2013.
Help employers find you! Check out all the jobs and post your resume.
WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to enable effective local treatment of ocular diseases, announced today the presentation of preclinical data which demonstrated that topical delivery of a small molecule receptor tyrosine kinase inhibitor (RTKi) formulated utilizing Kala’s proprietary mucosal-penetrating particle (MPP) technology significantly enhanced drug levels in the retina. Drug levels in the front of the eye were tunable depending on the release rate of MPP used. Kala presented these data at the Controlled-Release Society (CRS) 2013 Annual Meeting, in Honolulu, Hawaii on July 21-24, 2013.
Help employers find you! Check out all the jobs and post your resume.